WCN26-680 THALIDOMIDE TREATMENT FOR HEMODIALYSIS COMPLICATED WITH INTESTINAL VASCULAR DYSPLASIA

Read full text Summarise with VIRAT
Authors: Aiqiao Feng, Tai Li, Sai Xie
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Gastrointestinal (GI) angiodysplasia is a frequently encountered problem and the most frequent cause of recurrent bleeding in patients with hemodialysis, currently lacks standardized therapeutic protocols. Elevated vascular endothelial growth factor (VEGF) levels in hemodialysis populations and the demonstrated efficacy of thalidomide in GIVD management provide a potential therapeutic avenue. Nevertheless, clinical evidence regarding thalidomide's application for refractory gastrointestinal bleeding in this specific cohort remains scarce.

Fields of Study & Subjects

Gastrointestinal Bleeding Diagnosis and Treatment Abdominal vascular conditions and treatments Vascular Anomalies and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104190–104190
Publication date
25 March 2026
Language
EN